Pharming Group N.V./€PHARM
05:30
09:10
12:45
16:25
20:00
1D1W1MYTD1Y5YMAX
About Pharming Group N.V.
Pharming Group N.V. is a biotechnology company based in Leiden, Netherlands, focused on developing and commercializing innovative protein replacement therapies and precision medicines. The company's primary product, Ruconest, is an approved treatment for acute hereditary angioedema attacks, utilizing a recombinant form of the C1 esterase inhibitor. Established in 1988, Pharming leverages proprietary transgenic technology to produce human therapeutic proteins in the milk of genetically modified animals. With a strategic emphasis on rare diseases, the company aims to expand its pipeline through ongoing research and development activities. Pharming operates primarily in Europe and the United States, with partnerships and collaborations enhancing its global presence.
Ticker
€PHARM
Sector
Primary listing
AEX
Industry
Biotechnology
Headquarters
Employees
404
Website
PHARM Metrics
BasicAdvanced
€590M
-
-€0.02
0.53
-
Price and volume
Market cap
€590M
Beta
0.53
52-week high
€1.10
52-week low
€0.65
Average daily volume
7.6M
Financial strength
Current ratio
2.761
Quick ratio
1.996
Long term debt to equity
51.259
Total debt to equity
55.341
Interest coverage (TTM)
1.10%
Profitability
EBITDA (TTM)
14.437
Gross margin (TTM)
88.98%
Net profit margin (TTM)
-4.40%
Operating margin (TTM)
4.20%
Effective tax rate (TTM)
-290.62%
Revenue per employee (TTM)
€672,790
Management effectiveness
Return on assets (TTM)
1.99%
Return on equity (TTM)
-6.78%
Valuation
Price to revenue (TTM)
2.135
Price to book
2.69
Price to tangible book (TTM)
7.67
Price to free cash flow (TTM)
134.83
Free cash flow yield (TTM)
0.74%
Free cash flow per share (TTM)
0.64%
Growth
Revenue change (TTM)
24.13%
Earnings per share change (TTM)
30.18%
3-year revenue growth (CAGR)
16.67%
10-year revenue growth (CAGR)
29.99%
3-year earnings per share growth (CAGR)
10.95%
10-year earnings per share growth (CAGR)
-0.95%
Bulls say / Bears say
Pharming Group's total revenues increased by 21% to US$297.2 million in 2024, surpassing guidance, driven by record RUCONEST® revenue and strong Joenja® growth (pharming.com).
The acquisition of Abliva AB added KL1333 for mitochondrial DNA-driven primary mitochondrial diseases to Pharming’s late-stage clinical pipeline, aligning with their vision to become a leading global rare disease company (pharming.com).
Pharming Group appointed Fabrice Chouraqui as Chief Executive Officer in March 2025, bringing extensive biopharmaceutical leadership experience to drive the company's growth (pharming.com).
Despite revenue growth, Pharming Group reported a net loss of US$11.0 million for the year ended December 31, 2024, indicating ongoing profitability challenges (pharming.com).
The company's operating profit decreased to a loss of US$8.6 million in 2024 from a loss of US$5.4 million in 2023, reflecting increased operating expenses (pharming.com).
Pharming Group's cash and cash equivalents, restricted cash, and marketable securities decreased to US$108.9 million as of March 31, 2025, from US$169.4 million at the end of 2024, potentially impacting financial flexibility (nasdaq.com).
Data summarised monthly by Lightyear AI. Last updated on 4 Jul 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Pharming Group N.V. stock?
Pharming Group N.V. (PHARM) has a market cap of €590M as of July 28, 2025.
What is the P/E ratio for Pharming Group N.V. stock?
The price to earnings (P/E) ratio for Pharming Group N.V. (PHARM) stock is 0 as of July 28, 2025.
Does Pharming Group N.V. stock pay dividends?
No, Pharming Group N.V. (PHARM) stock does not pay dividends to its shareholders as of July 28, 2025.
When is the next Pharming Group N.V. dividend payment date?
Pharming Group N.V. (PHARM) stock does not pay dividends to its shareholders.
What is the beta indicator for Pharming Group N.V.?
Pharming Group N.V. (PHARM) has a beta rating of 0.53. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.